1. Search Result
Search Result
Results for "

MT-4

" in MedChemExpress (MCE) Product Catalog:

78

Inhibitors & Agonists

1

Biochemical Assay Reagents

10

Natural
Products

1

Antibodies

2

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111964
    Lenacapavir
    Maximum Cited Publications
    19 Publications Verification

    GS-6207

    HIV Infection
    Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir
  • HY-15592
    Cabotegravir
    10+ Cited Publications

    GSK-1265744; S/GSK1265744

    OAT HIV HIV Integrase Infection
    Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .
    Cabotegravir
  • HY-50101A
    Mavorixafor trihydrochloride
    5+ Cited Publications

    AMD-070 trihydrochloride; AMD-11070 trihydrochloride

    CXCR HIV Infection Endocrinology Cancer
    Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome .
    Mavorixafor trihydrochloride
  • HY-50101
    Mavorixafor
    5+ Cited Publications

    AMD-070; AMD-11070

    CXCR HIV Infection Endocrinology Cancer
    Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. Mavorixafor can be used for the study of WHIM syndrome .
    Mavorixafor
  • HY-113074

    Glycolithocholate sulfate; Sulfolithocholylglycine; SLCG

    HIV Endogenous Metabolite Infection Inflammation/Immunology
    Glycolithocholic acid 3-sulfate (SLCG) is a cholic acid derivative and a metabolite of glycolithocholic acid. Glycolithocholic acid 3-sulfate inhibits replication of HIV-1 in vitro. Glycolithocholic acid 3-sulfate can be used for the research of HIV infection and gallbladder disease .
    Glycolithocholic acid 3-sulfate
  • HY-50101C
    Mavorixafor hydrochloride
    5+ Cited Publications

    AMD-070 hydrochloride; AMD-11070 hydrochloride

    CXCR HIV Infection Cancer
    Mavorixafor (AMD-070) hydrochloride is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor hydrochloride also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 nM and 9 nM, respectively. Mavorixafor hydrochloride can be used for the study of WHIM syndrome .
    Mavorixafor hydrochloride
  • HY-128595

    Transglutaminase Cancer
    MT-4 is a derivative of a tissue transglutaminase (TG2) inhibitor. MT-4 targets the complex of TG2 and fibronectin (FN) (TG2/FN) and inhibits the adhesion of tumor cells to the matrix. MT-4 inhibits the adhesion of ovarian cancer (OC) cells to the peritoneum and increases the sensitivity of OC cells to paclitaxel.
    MT-4
  • HY-N2040
    (20R)-Protopanaxadiol
    1 Publications Verification

    Bacterial Interleukin Related Infection Inflammation/Immunology Cancer
    (20R)-Protopanaxadiol is a metabolite of ginsenosides. (20R)-Protopanaxadiol has anti-inflammatory and antibacterial activities, but shows no significant cytotoxicity against tumor cell lines. In addition, (20R)-Protopanaxadiol can inhibit the uptake of 2-deoxy-D-glucose (2-DG) .
    (20R)-Protopanaxadiol
  • HY-15355

    R 89439

    Reverse Transcriptase HIV Infection
    Loviride (R 89439) is a non-nucleoside reverse transcriptase inhibitor (NNRTI), with an IC50 of 0.3 µM for reverse transcriptase from HIV-1. Loviride (R 89439) inhibits HIV-1, HIV-2 and SIV replication in MT-4 cells .
    Loviride
  • HY-17605A
    Bictegravir sodium
    15+ Cited Publications

    GS-9883 sodium

    HIV Integrase HIV Infection
    Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
    Bictegravir sodium
  • HY-111964A
    Lenacapavir sodium
    Maximum Cited Publications
    19 Publications Verification

    GS-6207 sodium

    HIV Infection
    Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir sodium
  • HY-N16050

    Ethyl salvionolate A

    HIV Reverse Transcriptase HIV Integrase HIV Protease Infection
    Ethyl salvianolate A (Ethyl salvionolate A) is an anti-HIV-1 compound that can be extracted from the roots of Salvia yunnanensis. Ethyl salvianolate A inhibits P24 antigen in HIV-1 infected MT-4 cell cultures (EC50: 1.44 μg/mL). Ethyl salvianolate A inhibits HIV-1 replicative enzymes, with IC50s of 56.38 μM (Reverse transcriptase), 12.03 μM (Protease), 14.54 μM (Integrase), respectively .
    Ethyl salvianolate A
  • HY-106850

    AzdU; AzddU; CS-87

    HIV Infection
    3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC) . 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    3′-Azido-2′,3′-dideoxyuridine
  • HY-N6924
    Zingibroside R1
    1 Publications Verification

    HIV PIN1 Fungal GLUT Reactive Oxygen Species (ROS) Infection Neurological Disease Metabolic Disease Cancer
    Zingibroside R1 is an orally active triterpene saponin with multiple biological activities including antioxidant, anti-inflammatory, antiviral, and metabolic regulatory properties. Zingibroside R1 reduces the expression of PIN family members, inhibits the expression of PLT1/PLT2, WOX5, SHR, and SCR, disrupts auxin transport and distribution, triggers plant ROS responses, and inhibits root growth. Zingibroside R1 extends the lifespan of Caenorhabditis elegans, enhances its heat stress resistance, and improves its motor ability. Hydrogel derivatives of Zingibroside R1 inhibit the proliferation of Candida albicans by binding to its β-1,3-glucan and exhibit antifungal activity. Zingibroside R1 inhibits GLUT1-mediated uptake and alleviates liver injury. Zingibroside R1 can be used in research related to neurodegenerative diseases, vulvovaginal candidiasis, acute liver injury, Ehrlich ascites tumor and HIV-1 infection [4] .
    Zingibroside R1
  • HY-159059

    c-Myc Bcl-2 Family Eukaryotic Initiation Factor (eIF) Survivin β-catenin MMP Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Ganoderma Lucidum/Reishi Extract is a Ganoderma lucidum extract. Ganoderma Lucidum/Reishi Extract reduces the expression of c-Myc, BCL-2, BCL-XL, TERT, PDGFB, eIF4G, Survivin, β-catenin, and eIF4E. Ganoderma Lucidum/Reishi Extract downregulates the gene expression of MMP-9. Ganoderma Lucidum/Reishi Extract upregulates the expression of IL8. Ganoderma Lucidum/Reishi Extract is applicable to the research of inflammatory breast cancer. Ganoderma Lucidum is used in the research of various diseases, such as allergy, arthritis, hypertension, neurasthenia, inflammation, and cancer .
    Ganoderma Lucidum/Reishi Extract
  • HY-177098

    HIV HIV Integrase Infection
    Lepetegravir (Example 24) is a HIV integrase inhibitor. Lepetegravir has antiviral effects (EC50: 0.98 nM in MT-4 cells) .
    Lepetegravir
  • HY-150759

    HIV Infection
    HIV-1 inhibitor-45 is a potent HIV-1 RNase H inhibitor with an IC50 value of 0.067 μM. HIV-1 inhibitor-45 shows an antiviral activity. HIV-1 inhibitor-45 shows poor cell permeability (with an apparent permeability coefficient (Papp) lower than 0.48 × 10 −6 cm/s) .
    HIV-1 inhibitor-45
  • HY-RS08745

    Small Interfering RNA (siRNA) Others

    MT4 Human Pre-designed siRNA Set A contains three designed siRNAs for MT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MT4 Human Pre-designed siRNA Set A
    MT4 Human Pre-designed siRNA Set A
  • HY-12108

    HIV Integrase HIV Infection
    S 1360 is a potent and selective inhibitor of HIV-1 integrase. S 1360 inhibits the catalytic activity of purified integrase ( IC50: 20 nM). The EC50, and CC50 of S 1360 in MTT assay (MT-4 cells infected with HIV-1 IIIB) are 200 nM and 12 μM, respectively. S 1360 has antiviral activity against both X4 tropic and R5 tropic strains, as well as NRTI, NNRTI and PI drug-resistant variants .
    S 1360
  • HY-17605AR

    GS-9883 sodium (Standard)

    Reference Standards HIV Integrase HIV Infection
    Bictegravir (sodium) (Standard) is the analytical standard of Bictegravir (sodium). This product is intended for research and analytical applications. Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC50 of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .
    Bictegravir sodium (Standard)
  • HY-146353

    HIV Infection Inflammation/Immunology
    HIV-1 inhibitor-29 (compound 14d2) is a potent HIV-1 inhibitor with an EC50 of 2.18 μM for HIV-1 IIIB. HIV-1 inhibitor-29 has high anti-resistance profile toward F227L/V106A strain (EC50 = 0.974 μM), and exhibits low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 inhibitor-29 can be used for researching AIDS .
    HIV-1 inhibitor-29
  • HY-149866

    Cytochrome P450 HIV Reverse Transcriptase Infection
    HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC50 less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC50: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch .
    HIV-1 inhibitor-58
  • HY-18666

    HIV Infection
    D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).
    D77
  • HY-15355R

    R 89439 (Standard)

    Reverse Transcriptase HIV Reference Standards Infection
    Loviride (Standard) is the analytical standard of Loviride. This product is intended for research and analytical applications. Loviride (R 89439) is a non-nucleoside reverse transcriptase inhibitor (NNRTI), with an IC50 of 0.3 μM for reverse transcriptase from HIV-1. Loviride (R 89439) inhibits HIV-1, HIV-2 and SIV replication in MT-4 cells .
    Loviride (Standard)
  • HY-152539

    HIV Infection
    HIV-1 inhibitor-54 is a potent HIV-1 inhibitor. HIV-1 inhibitor-54 has anti-HIV activity in MT-4 cells against WT HIV-1 (strain IIIB) with an EC50 value of 0.032 μM. HIV-1 inhibitor-54 can be used for the research of virus infection .
    HIV-1 inhibitor-54
  • HY-125810

    HIV Reverse Transcriptase Infection Inflammation/Immunology
    4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside reverse transcriptase (RT) inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC50 of 98 nM in MT-4 cells for anti-HIV-1 activity . 4'-Ethynyl-2'-deoxyadenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    4'-Ethynyl-2'-deoxyadenosine
  • HY-RS19301

    Small Interfering RNA (siRNA) Others

    Mt4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mt4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mt4 Mouse Pre-designed siRNA Set A
    Mt4 Mouse Pre-designed siRNA Set A
  • HY-RS25792

    Small Interfering RNA (siRNA) Others

    Mt4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mt4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mt4 Rat Pre-designed siRNA Set A
    Mt4 Rat Pre-designed siRNA Set A
  • HY-144714

    HIV Infection
    HIV-1 inhibitor-18 (compound II-13c) is a potent HIV-1 capsid inhibitor with an EC50 value of 5.14 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >9.51) .
    HIV-1 inhibitor-18
  • HY-144715

    HIV Infection
    HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor with an EC50 value of 2.57 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >8.55) .
    HIV-1 inhibitor-17
  • HY-178341

    Reverse Transcriptase HIV Infection
    NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type HIV-1 (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research .
    NNRT-IN-13
  • HY-175667

    HIV Reverse Transcriptase Infection
    NNRT-IN-12 (compound 19) is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor with an IC50 value of 0.107 μM for WT HIV-1 RT. NNRT-IN-12 shows anti-HIV-1 activity with EC50 value of 14.1, 5.03, 7.64, 27.1 nM for L100I, K103N, Y181C, Y188L mutant HIV-1 strains, respectively. NNRT-IN-12 shows cytotoxicity .
    NNRT-IN-12
  • HY-162525

    HIV Protease Infection
    GS-9770 is an orally active inhibitor for HIV protease with Ki of 0.16 nM. GS-9770 exhibits antiviral activity aginst HIV-1 strains and HIV-2 strains with EC50 of 1.9-26 nM, and 26 nM. GS-9770 is metabolic stable in human liver microsomes. GS-9770 exhibits good pharmacokinetic characters in Sprague Dawley rats .
    GS-9770
  • HY-147723

    HIV Infection
    HIV-1 inhibitor-39 (compound 3c) is a potent HIV-1 inhibitor with an EC50 of >112.88 µM. HIV-1 inhibitor-39 shows anti-RT (HIV-1 reverse transcriptase) activities with an IC50 of 15.75 µM. HIV-1 inhibitor-39 shows cytotoxicity for MT-4 cells with an CC50 of 112.9 µM .
    HIV-1 inhibitor-39
  • HY-15592R

    GSK-1265744 (Standard); S/GSK1265744 (Standard)

    OAT Reference Standards HIV HIV Integrase Infection
    Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .
    Cabotegravir (Standard)
  • HY-147653

    HIV Integrase Infection
    Integrase-LEDGF/p75 allosteric inhibitor 1 (Compound 31h) is an orally active integrase-LEDGF/p75 (IN-LEDGF/p75) allosteric inhibitor. Integrase-LEDGF/p75 allosteric inhibitor 1 inhibits HIV-1 DNA integration and shows antiviral activity with an EC50 of 3.9 nM against HIV-1 recombinant molecular clone NL432 .
    Integrase-LEDGF/p75 allosteric inhibitor 1
  • HY-N11288

    HIV Infection
    Methyl salvionolate A is a potent inhibitor of HIV-1. Methyl salvionolate A inhibits P24 antigen in HIV-1 infected MT-4 cell with an EC50 of 1.62 μg/ml. Methyl salvionolate A also inhibits HIV-1 reverse transcriptase, protease and integrase with IC50s of 50.58, 10.73 and 7.58 μg/ml, respectively .
    Methyl salvionolate A
  • HY-171835

    HIV HIV Protease Infection
    DPC 684 is a potent and selective HIV-1 protease inhibitor (IC90 = 5.7-40 nM, Ki = 0.021 nM). DPC 684 competitively inhibits HIV-1 protease and blocks viral polyprotein cleavage. DPC 684 has low protein binding and broad-spectrum inhibition against a variety of wild-type and mutant HIV-1 proteases. DPC 684 has low protein binding and broad-spectrum inhibition (IC90 = 1.9-6.3 nM). DPC 684 has research significance for HIV .
    DPC 684
  • HY-175351

    HIV Reverse Transcriptase Infection
    HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC50 of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM .
    HIV-1-IN-83
  • HY-146352

    HIV Infection Inflammation/Immunology
    HIV-1 inhibitor-28 (compound 14j2) is a highly potent and selective HIV-1 inhibitor with an EC50 of 58 nM for WT HIV-1 strain and an IC50 of 3.37 μM for HIV-1 WT reverse transcription (RT). HIV-1 inhibitor-28 exhibits relatively low cytotoxicity in MT-4 cells (CC50 = 38.6 μM). HIV-1 inhibitor-28 can be used for researching AIDS .
    HIV-1 inhibitor-28
  • HY-135858
    SARS-CoV-IN-3
    1 Publications Verification

    SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells .
    SARS-CoV-IN-3
  • HY-146019

    HIV Infection
    HIV-1 inhibitor-24 (compound S-12a) is a highly potent HIV-1 reverse transcriptase, with an IC50 value of 9.5 nM. HIV-1 inhibitor-24 has high antiretroviral activity against WT HIV-1 with an EC50 of 1.6 nM, and exhibits relatively low cytotoxicity with a CC50 of 9.07 μM in MT-4 cells. HIV-1 inhibitor-24 is well tolerated at a dose of 2 g/kg in mice and has a significant cardiovascular safety .
    HIV-1 inhibitor-24
  • HY-135856
    SARS-CoV-IN-2
    1 Publications Verification

    SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities .
    SARS-CoV-IN-2
  • HY-N12260

    HIV Bacterial Infection
    Benanomicin A is a microbial metabolite and can be isolated from Actinomycetes.Benanomicin has antifungal activitya and inhibits HIV-1 viral infection in MT-4 cells .
    Benanomicin A
  • HY-10891

    HIV Infection Inflammation/Immunology
    HIV-1 inhibitor-61 (2c) is a HIV-1 reverse transcriptase inhibitor, with an EC50 of 0.07 nM in NL4-3 wt MT-4 cells .
    HIV-1 inhibitor-61
  • HY-137309

    HIV Others
    4-Deoxy-4α-phorbol is a tetracyclic diterpene found in E. desmondi. It has been used in the semisynthesis of inhibitors of the HIV-1-induced cytopathic effect on MT-4 cells and 4α-phorbol esters .
    4-Deoxy-4α-phorbol
  • HY-146091

    HIV Infection
    HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells. HIV-1 inhibitor-34 can be used for researching AIDS .
    HIV-1 inhibitor-34
  • HY-146090

    HIV Infection
    HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM for HIV-1 and a CC50 of 18 μM in MT-4 cells. HIV-1 inhibitor-33 can be used for researching AIDS .
    HIV-1 inhibitor-33
  • HY-146019A

    HIV Infection
    HIV-1 inhibitor-25 (compound R-12a) is a highly potent HIV-1 reverse transcriptase, with an IC50 value of 0.1061 μM. HIV-1 inhibitor-25 has high antiretroviral activity against WT HIV-1 with an EC50 of 13.6 nM, and exhibits relatively low cytotoxicity with a CC50 of 33.13 μM in MT-4 cells. HIV-1 inhibitor-25 also has inhibitory activity against HIV-1 mutant strains (L100I, K103N, Y181C, Y188L, E138K, F227L+V106A) with EC50 of 0.1961 ~ 5.8136 μM. HIV-1 inhibitor-25 can be used for researching AIDS .
    HIV-1 inhibitor-25
  • HY-120812

    HIV Protease Infection
    HIV-IN-11 is part of the hydroxylaminoglutaramide (HAPA) transition state isomeric series of HIV protease inhibitors and is a potent and selective inhibitor of HIV-1 protease. HIV-IN-11 competitively inhibits HIV-1 PR (Ki: 0.049 nM) and potently inhibits replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. HIV-IN-11 displays a longer half-life than indinavir sulfate in animal models and serves as a promising second-generation HIV protease inhibitor .
    HIV-IN-11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: